Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Uveitis Treatment Market: By Drug Class, By Disease Type By Cause, By Distribution channel and Geography.
Uveitis Treatment Market size was valued at 697 million in 2023 and is poised to grow at a significant CAGR of 5.7% from 2024 to 2030. Market players are developing novel molecules that can treat uveitis conditions in order to enhance their sales revenue. Companies are focusing on the development of the various drugs in the treatment of the uveitis. For instance, Aurinia Pharmaceuticals Inc. developing Luvenia, a calcineurin inhibitor for the treatment of noninfectious uveitis. Recently it has completed its phase-II clinical trials. Similarly, other pipeline drugs such as EMEA, DE-109, Gevokizumab, Peptide B27PD are being developed by different companies.
Considering the aforementioned factors global uveitis treatment market is expected to grow at the significant rate during the forecast period. Uveitis is the term that describes a group of inflammatory diseases that affect the eye and produces swelling. Uveitis can reduce sight and may cause vision loss. Causes of uveitis include infections such as brucellosis, leptospirosis, syphilis, tuberculosis, autoimmune diseases such as sarcoidosis, Crohn's disease, multiple sclerosis, arthritis, ankylosing spondylitis, and psoriatic arthritis. In addition, uveitis is also caused by drugs such as rifabutin and moxifloxacin. Uveitis affects uvea, lens, retina, optic nerve, and vitreous. Uveitis can be classified into anterior uveitis, intermediate uveitis, posterior uveitis and pan-uveitis based on part of inflammation.
Study Period
2024-2030Base Year
2023CAGR
5.7%Largest Market
North AmericaFastest Growing Market
Asia Pacific
The main driver for the growth of uveitis market is the rise in prevalence and complications related to uveitis. In addition, increase in prevalence rates, market players betting heavily on research and development to develop new drugs, an introduction of biologics into the market, fast approval of the drugs are fueling the market growth of uveitis treatment market. According to the Ocular Immunology and Uveitis Foundation, worldwide 2,359,242 people are estimated to have the disorder. Even there are significant advances in research and therapeutics, a prevalence of blindness secondary to uveitis has not been reduced in the past thirty years. However, few factors are restraining the growth of the market such as side effects of the drugs, eye irritation and lack of awareness about eye disorders in undeveloped regions, lack of sufficient healthcare infrastructure is hindering the uveitis treatment system market.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market CAGR |
5.7% |
By Drug Class |
|
By Disease Type |
|
By Cause |
|
Distribution channel |
|
Download Free Sample Report
The Uveitis Treatment Market size was valued at 697 million in 2023 and is poised to grow at a significant CAGR of 5.7% from 2024 to 2030.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1.Executive Summary |
2.Global Uveitis Treatment Market Introduction |
2.1.Global Uveitis Treatment Market - Taxonomy |
2.2.Global Uveitis Treatment Market - Definitions |
2.2.1.Drug Class |
2.2.2.Disease Type |
2.2.3.Cause |
2.2.4.Region |
3.Global Uveitis Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Uveitis Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Uveitis Treatment Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Corticosteroids |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Immunosuppressant |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Monoclonal antibodies |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Antibiotics |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Antivirals |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Antifungal |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Analgesics |
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
6.Global Uveitis Treatment Market By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Anterior Uveitis |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Posterior Uveitis |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Intermediate Uveitis |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Panuveitis |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7.Global Uveitis Treatment Market By Cause, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Infectious Uveitis |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Non-Infectious Uveitis |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8.Global Uveitis Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Uveitis Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Corticosteroids |
9.1.2.Immunosuppressant |
9.1.3.Monoclonal antibodies |
9.1.4.Antibiotics |
9.1.5.Antivirals |
9.1.6.Antifungal |
9.1.7.Analgesics |
9.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Anterior Uveitis |
9.2.2.Posterior Uveitis |
9.2.3.Intermediate Uveitis |
9.2.4.Panuveitis |
9.3. Cause Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Infectious Uveitis |
9.3.2.Non-Infectious Uveitis |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Uveitis Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Corticosteroids |
10.1.2.Immunosuppressant |
10.1.3.Monoclonal antibodies |
10.1.4.Antibiotics |
10.1.5.Antivirals |
10.1.6.Antifungal |
10.1.7.Analgesics |
10.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Anterior Uveitis |
10.2.2.Posterior Uveitis |
10.2.3.Intermediate Uveitis |
10.2.4.Panuveitis |
10.3. Cause Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Infectious Uveitis |
10.3.2.Non-Infectious Uveitis |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Uveitis Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Corticosteroids |
11.1.2.Immunosuppressant |
11.1.3.Monoclonal antibodies |
11.1.4.Antibiotics |
11.1.5.Antivirals |
11.1.6.Antifungal |
11.1.7.Analgesics |
11.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Anterior Uveitis |
11.2.2.Posterior Uveitis |
11.2.3.Intermediate Uveitis |
11.2.4.Panuveitis |
11.3. Cause Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Infectious Uveitis |
11.3.2.Non-Infectious Uveitis |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Uveitis Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Corticosteroids |
12.1.2.Immunosuppressant |
12.1.3.Monoclonal antibodies |
12.1.4.Antibiotics |
12.1.5.Antivirals |
12.1.6.Antifungal |
12.1.7.Analgesics |
12.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Anterior Uveitis |
12.2.2.Posterior Uveitis |
12.2.3.Intermediate Uveitis |
12.2.4.Panuveitis |
12.3. Cause Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Infectious Uveitis |
12.3.2.Non-Infectious Uveitis |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Uveitis Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Corticosteroids |
13.1.2.Immunosuppressant |
13.1.3.Monoclonal antibodies |
13.1.4.Antibiotics |
13.1.5.Antivirals |
13.1.6.Antifungal |
13.1.7.Analgesics |
13.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Anterior Uveitis |
13.2.2.Posterior Uveitis |
13.2.3.Intermediate Uveitis |
13.2.4.Panuveitis |
13.3. Cause Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Infectious Uveitis |
13.3.2.Non-Infectious Uveitis |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.AbbVie, Inc. |
14.2.2.Alcon, a Novartis Company |
14.2.3.Allergan PLC |
14.2.4.Bausch & Lomb, Inc. |
14.2.5.Enzo Biochem, Inc. |
14.2.6.Hanbell Precise Machinery Co. Ltd. |
14.2.7.Psivida Corporation |
14.2.8.Regeneron Pharmaceuticals, Inc. |
14.2.9.Santen Pharmaceutical Co., Ltd. |
14.2.10.TopiVert Ltd. |
14.2.11.XOMA Corporation |
14.2.12.Novartis AG |
14.2.13.Eyegate Pharmaceuticals, Inc. |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players